Data from The BMJ - Curated by EPG Health - Last updated 29 January 2019
Accrediting Body
BMJ Learning - British Medical Learning
Expected length
60 minutes
Award
1 credit
Subscription
Register (90)
Through interactive case histories, learn how to advise men who are worried about prostate cancer, and the treatment options available to men diagnosed with clinically localised cancer. With multimedia video.
After completing this module, you should know:
- How to advise men who are worried about prostate cancer
- What information you should give them
- The treatment options available to men diagnosed with clinically localised cancer.
| Category | Value |
|---|---|
| Credit type | Credit |
| Registration with provider required | Yes |
| Certificate available | Yes |
| Author(s) | BMJ Learning with the NHS prostate cancer management programme |
| Multi session | No |
| Intended audience(s) | General Practitioner |
Learning Zones
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
Chronic Lymphocytic Leukaemia (CLL)
Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more
+ 1 more
Biosimilars Knowledge Centre
What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.
CDK 4/6 inhibitors in metastatic breast cancer
The CDK 4/6 Inhibitors in Metastatic Breast Cancer Learning Zone provides insights and information for metastatic breast cancer (mBC) and CDK 4/6 signalling. This includes the burden and pathophysiology of the disease, the role of CDK 4/6 in cell proliferation and an overview of the CDK 4/6 inhibitors that have been approved for the management of mBC.
Comments
You will need to login, to leave a comment.
epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.